Citations

Clear

948 citation(s) found for "Li, Bryan".

National Cancer Statistics: American College of Surgeons Cancer Programs Annual Report from 2022 Participant User File
Habermann, Elizabeth B, Day, Courtney N. , Palis, Bryan E., Boffa, Daniel, Alanee, Shaheen , Habermann, Elizabeth B. , Boffa, Daniel J. , Hieken, Tina J. , Weigel, Ronald J. , Boughey, Judy C.

Mayo Clinic

Journal of the American College of Surgeons | January 21, 2026 | Volume: 242 | Issue: 6 | Pages: 1614-1630

10.1097/xcs.0000000000001747 | PMID 41562441 Get It

DOP085 Baseline predictors and clinical outcomes of risankizumab dose optimization: a real-world multicenter retrospective study
Johnson, A, Ramesh, P R, Said, Hyder , Huang, K, Devi, Jalpa, Pekow, J R, Alhobayb, T, Bassmeyer, B, Mohamed, M, Shivashankar, Raina , Rathi, J, Luu, Bryan Christopher, Khan, A , Loftus, E, Bishu, S, Patel, A, Shukla, R. , Yarur, Andrés , Ungaro, R, Yarur, Andres J , Pekow, Joel , Alhobayb, Tamara Y. , Luu, Bryan C. , Bishu, Shrinivas , Ungaro, Ryan C. , Deepak, Parakkal

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.122 Get It

Abstract Background A subset of risankizumab (RZB)-treated patients experience suboptimal or secondary loss of response to standard dosing. We explored factors associated with future RZB dose-optimization, and outcomes of optimization in a multicenter consortium of adults with Crohn’s Disease (CD). Methods Baseline characteristics at time of RZB initiation and subsequent clinical, endoscopic, and biochemical outcomes were collected in a multi-center cohort. Outcomes for dose-optimized RZB were reported as clinical response and remission (based on HBI or PGA when HBI unavailable), endoscopic remission (based on SEMA-CD or absence of ulcers when SEMA-CD not available), and biochemical response. Characteristics were compared between standard and dose-optimized groups using chi-square and two-sample t-tests. Additional models adjusting for age and sex assessed predictors of dose optimization. Results We identified 309 patients treated with standard dose and 58 for whom dose-optimized RZB was recommended. Of the 58, 29 were excluded from outcomes analysis due to lack of follow-up (n = 19) or insurance denial of dose optimization (n = 10). Demographic information is outlined in Table 1. Baseline characteristics associated with future dose optimization included number of prior advanced therapies (ATs) (OR, 1.29, p < 0.001), prior anti-TNF (OR,4.06; p = 0.022), and prior ustekinumab (UST) use (OR,1.82; p = 0.053) (Table 2). The 29 patients included in the outcome analysis received dose-optimized RZB for primary non-response (n = 2), partial response (n = 23), or secondary loss of response (n = 4) after a median of 321 days (IQR, 234-440) from index RZB start. Median follow-up after dose optimization was 217 days (IQR, 147-331). All patients were AT-exposed (Table 1). Baseline clinical symptoms were present in 27 patients (93.1%), with median HBI of 6.5 (IQR, 6.0-8.0). Active endoscopic disease was observed in 11/12 patients (91.7%) who had baseline endoscopy. Dosing was every 4 weeks in 19 (65.5%), every 6 weeks in 9 (31.0%), and combined IV re-induction plus every 4-weeks in 1 (3.4%) patient. Clinical response and remission was seen in 16 (55.2%) and 12 (41.4%) patients, respectively. A ≥ 50% CRP reduction was seen in 5/12 (41.7%) patients with baseline elevated CRP. Among 7 patients with baseline active endoscopic disease with available follow-up, 3 (42.9%) achieved endoscopic remission. No adverse events were reported. Conclusion In this multi-center retrospective cohort, prior AT-exposure (especially anti-TNF) was associated with need for RZB dose-optimization. Dose optimization successfully captured clinical response in a significant proportion of patients who experienced partial response or loss of response to RZB. Conflict of interest: Johnson, Amanda: Research grant: Abbvie, Spyre Therapeutics Ramesh, Prajith Raj: None Said, Hyder: No conflict of interest Huang, Katherine: No conflict of interest Devi, Jalpa: none Pekow, Joel R.: CVS Health - Consulting Abbvie, Eli Lilly, Pfizer, Johnson and Johnson - Stocks Alhobayb, Tamara: No conflict of interest Bassmeyer, Blake: No conflict of interest Mohamed, Mouhand: No conflict of interest Shivashankar, Raina: Abbvie and BMS - speaker bureau Janssen and Celltrion - grant for IBD fellowship funding Pfizer - consultant Rathi, Jaya: No conflict of interest Luu, Bryan: No conflict of interest Khan, Abdul: No conflict of interest Loftus, Jr, Edward: Grant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, UCB. Personal Fees: AbbVie, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Iterative Scopes, Janssen, Ono Pharma, Pfizer, Sun Pharma, Takeda, UCB. Bishu, Shrinivas: None Patel, Anish: speaker: abbvie, J & J, Lilly, BMS, Pfizer, Phathom, Takeda consultant: abbvie Shukla, Richa: Speakers bureau - Abbvie and Lilly Yarur, Andres: Personal Fees: Consultant for Takeda, Pfizer, Roche, Merck, Abbvie, Eli Lilly. Bristol Myers Squibb, Celltrion, Johnson and Johnson. Ungaro, Ryan: Personal Fees: AbbVie, Bristol Myers Squibb, Genentech, Lilly, Pfizer, Janssen, Takeda Deepak, Parakkal: Parakkal Deepak has received research support under a sponsored research agreement unrelated to the data in the abstract from AbbVie, Johnson and Johnson, Sanofi, Merck, Teva, Direct Biologics, Tr1x, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Eli Lilly, AstraZeneca, Spyre and Agomab, has received consulting fees from Johnson and Johnson, Abbvie, Merck, Sobi, Celltrion, Fresenius Kabi, Asahi Kasei Pharma, Sandoz and CorEvitas, LLC and has served on the board of the Srategic Alliance for Intercultural Advocacy in GI.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
Taplin, Mary-Ellen, Riaz, Irbaz Bin , Rumble, R. Bryan , Naqvi, Syed Arsalan Ahmed , Hope, MD Thomas A., Dias, Mariane Fontes , He, Huan, Hotte, Sebastién J. , Emamekhoo, Hamid, Murad, M. Hassan, Celano, Paul , Kungel, Terry M. , Hentzen, Steve, Serzan, Michael , Parikh, Rahul A., Murad, M. Hassan , Hope, Thomas A. , Emamekhoo, Hamid , Dias, Mariane Sousa Fontes , Hope, Thomas A , Emamekhoo, Hamid , Murad, M Hassan , Serzan, Michael Thomas , Parikh, Rahul A , He, Huan , Riaz, Irbaz B , Hotte, Sebastien J , Rumble, R Bryan , Taplin, Mary‐Ellen , Kungel, Terry

Mayo Clinic

Journal of Clinical Oncology | January 20, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1200/jco-25-02693 | PMID 41557978 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at www.asco.org/genitourinary-cancer-guidelines .
Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases
Rajan, Sharika, Chung, Hye‐Jung, Wu, Zhichao , Dazelle, Karen , Abdullaev, Zied , Tyagi, Manoj, Ferrone, Christina K. , Raffeld, Mark , Lee, Ina, Chen, Jie , Cathcart, Sahara , Giannini, C., Nguyen, Aivi, Gökden, Murat , Perry, A., Fernandes, Igor Lima , Putnam, Angelica R. , Kurek, Kyle C., Green, Richard M, Lucas, Calixto-Hope, González-Gómez, Ignacio, Lopez, G., Ra, Prayson, Yeaney, Gabrielle , Dermawan, Josephine Kam Tai, Chkheidze, Rati , Appin, Christina , Uhlmann, Erik J. , Taliansky, A , Blessing, Melissa M. , Mohila, Carrie, Deisch, Jeremy , Andreiuolo, Felipe, Crawford, John R, Stemmer‐Rachamimov, Anat , Lakis, Nelli S., Re, Schmidt, Chacko, Geeta, Newbury, Robert, Neill, Stewart G. , Morales, Bryan , Fecher, Roger , Sloan, Emily A. , Solomon, David A, Nasrallah, MacLean, Quezado, Martha, Aldape, Kenneth, Solomon, David A. , Chen, Jie , Giannini, Caterina , Perry, Arie , Chkheidze, Rati , Deisch, Jeremy , Solomon, David A , Aldape, Kenneth , Jones, Karra A , López, Giselle Y. , Wu, Zhichao, Singh, Omkar, Gagan, Jeffrey , Nguyen, Aivi, Perry, Arie , Green, Richard M., Eberhart, Charles G. , Lucas, Calixto-Hope C. , Jones, Karra A. , Mohila, Carrie , Cotter, Jennifer A. , Andreiuolo, Felipe , Crawford, John R, Mount, Christopher , Lakis, Nelli S., Schmidt, Robert, Chacko, Geeta , Nasrallah, MacLean P. , Quezado, Martha , Fonseca, Adriana

Mayo Clinic

Neuro-Oncology | January 17, 2026 | Volume: 28 | Issue: 4 | Pages: 939-951

10.1093/neuonc/noag001 | PMID 41569358 Get It

Abstract Background Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. Methods We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. Results ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. Conclusions This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
Genomic signatures in Variovorax enabling colonization of the Populus endosphere
Beals, Delaney G. , Hochanadel, Leah H. , Piatkowski, Bryan , Doktycz, Mitchel J. , Pelletier, Dale, Piatkowski, Bryan T , Doktycz, Mitchel J , Pelletier, Dale A , Carper, Dana L. , Jawdy, Sara S. , Klingeman, Dawn M. , Weston, David J.

Mayo Clinic

mSystems | January 16, 2026 | Volume: 11 | Issue: 2 | Pages: No page available

10.1128/msystems.01605-25 | PMID 41543249 Get It

ABSTRACT Microbial colonization of plant roots involves strong selective pressures that shape the structure and function of root-associated communities. In particular, the endosphere represents a highly selective environment requiring host entry and in planta persistence. However, strain-specific microbial traits that enable endosphere colonization remain poorly understood. Here, we use a defined, genome-resolved community of 28 Variovorax strains isolated from the roots of Populus deltoides and Populus trichocarpa (poplar trees) to determine which strains partition between rhizosphere and endosphere compartments and to identify the genomic traits associated with endosphere specialization. By combining strain-resolved metagenomic profiling, comparative genomics, and functional assays, we demonstrate that dominant endosphere colonizers are enriched in genes related to nutrient metabolism, redox balance, transcriptional regulation, and a conserved L-fucose utilization pathway experimentally shown to enhance root colonization. Not all strains succeed through the same strategy. Community-wide functional profiling revealed a distinct and reduced set of traits in the endosphere, including orthogroups associated with low-abundance strains that were overlooked in strain-level analyses. These findings reveal that multiple ecological strategies, such as metabolic competition, regulatory adaptation, and niche specialization, can support endosphere colonization. Our results advance the understanding of how bacterial colonization traits are distributed and deployed within a plant microbiome and suggest that host filtering selects for distinct, and sometimes complementary, microbial strategies. This work supports a shift toward mechanistic, genome-resolved models of microbiome assembly and offers a framework for linking microbial function to host colonization success. IMPORTANCE Plants often depend on diverse microbial partners to support their growth, resilience, and adaptation to changing environments. Among these microbes, some bacteria inhabit the rhizosphere (the narrow zone around roots where microbes interact with the plant) while others are able to enter and persist within root tissues. The traits that distinguish these two lifestyles remain poorly understood. In this study, we examined a group of related Variovorax strains from poplar tree root microbiomes to ask why some rhizosphere-associated strains also become successful endosphere colonizers. We found that strains appear to succeed through different strategies: some may benefit from rapid growth on plant-derived carbon sources, while others may rely on stress tolerance or fine-tuned regulation. These results suggest that there is no single path from the rhizosphere into the root interior, but rather multiple strategies shaped by the host environment. Understanding this diversity can inform efforts to design resilient plant-microbe communities.
Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers
Tripathi, Utkarsh , Suda, Masayoshi , Kulshreshtha, Vagisha , Piatkowski, Bryan T, Giorgadze, Nino, Inman, Christina L., Gasek, Nathan , Xu, Ming, Johnson, Kurt O. , Pirtskhalava, Tamar , Chaib, Selim , Prata, Larissa P. G. Langhi, Zhu, Yi , Kandhaya‐Pillai, Renuka , Tullius, S., Wyles, Saranya P. , Majji, Rambabu, Tchkonia, Tamar, Kirkland, James L., Inman, Christina, Chaib, Selim , Yalamanchili, Hari Krishna , Zhu, Yi , Suda, Masayoshi , Tripathi, Utkarsh , Piatkowski, Bryan , Palmer, Allyson K. , Prata, Larissa , Rambabu, Majji , Allison, David B. , Tchkonia, Tamar , Kirkland, James L.

Mayo Clinic

Aging Cell | December 30, 2025 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/acel.70358 | PMID 41462575 Get It

ABSTRACT The senescent cell (SC) fate is linked to aging, multiple disorders and diseases, and physical dysfunction. Senolytics, agents that selectively eliminate 30%–70% of SCs, act by transiently disabling the senescent cell antiapoptotic pathways (SCAPs), which defend those SCs that are proapoptotic and pro‐inflammatory from their own senescence‐associated secretory phenotype (SASP). Consistent with this, a JAK/STAT inhibitor, Ruxolitinib, which attenuates the pro‐inflammatory SASP of senescent human preadipocytes, caused them to become “senolytic‐resistant”. Administering senolytics to obese mice selectively decreased the abundance of the subset of SCs that is pro‐inflammatory. In cell cultures, the 30%–70% of human senescent preadipocytes or human umbilical vein endothelial cells (HUVECs) that are senolytic‐resistant (to Dasatinib or Quercetin, respectively) had increased p16 INK4a , p21 CIP1 , senescence‐associated β‐galactosidase (SAβgal), γH2AX, and proliferative arrest similarly to the total SC population (comprising senolytic‐sensitive plus‐resistant SCs). However, the SASP of senolytic‐resistant SCs entailed less pro‐inflammatory/apoptotic factor production, induced less inflammation in non‐senescent cells, and was equivalent or richer in growth/fibrotic factors. Senolytic‐resistant SCs released less mitochondrial DNA (mtDNA) and more highly expressed the anti‐inflammatory immune evasion signal, glycoprotein non‐melanoma‐B (GPNMB). Transplanting senolytic‐resistant SCs intraperitoneally into younger mice caused less physical dysfunction than transplanting the total SC population. Because Ruxolitinib attenuates SC release of proapoptotic SASP factors, while pathogen‐associated molecular pattern factors (PAMPs) can amplify the release of these factors rapidly (acting as “senosensitizers”), senolytic‐resistant and senolytic‐sensitive SCs appear to be interconvertible.
Skin Biopsy for Phosphorylated α‐Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice
Botha, Hugo, Barnard, Leland R , Reichard, R. Ross, Larsen, Rachel A. , Cogan, Wendy, Switzer, Aaron , Ramanan, Vijay K., Neth, Bryan J. , Townley, Ryan , Savica, Rodolfo , Jones, D., Miyagawa, Toji , Fields, Julie A. , Vernon, Cynthia J. , Trottier, Zachary A., Lowe, Val J. , Knopman, David S., Petersen, Ronald C., Dickson, Dennis W., Kantarci, Kejal, Graff‐Radford, Jonathan, Boeve, B. F., Kantarci, Kejal , Rigby, Michael J. , Larsen, Rachel, Savica, Rodolfo , Miyagawa, Toji , St Louis, E K , Kantarci, Kejal , Graff-Radford, Jonathan , McCarter, Stuart J , Neth, Byran J. , Switzer, Aaron R , Botha, Hugo , Reichard, R. Ross , Ramanan, Vijay K. , Jones, David T. , Vernon, Cynthia, Trottier, Zachary, Louis, Erik K. St. , Knopman, David S. , Petersen, Ronald C. , Graff‐Radford, Jonathan , McCarter, Stuart J.

Mayo Clinic

Movement Disorders | December 29, 2025 | Volume: 41 | Issue: 4 | Pages: 962-971

10.1002/mds.70158 | PMID 41459992 Get It

Abstract Background Immunohistochemically detected phosphorylated α‐synuclein (p‐α‐syn) in cutaneous nerves has been found in >95% of patients meeting consensus criteria for dementia with Lewy bodies (DLB); however, its performance in prodromal stages (mild cognitive impairment‐Lewy body [MCI‐LB]) and clinical practice is unknown. Objective We evaluated skin biopsy for p‐α‐syn in a convenience cohort of patients with suspected MCI‐LB or DLB in a tertiary care setting. Methods 53 patients underwent commercially available skin biopsy for skin nerve p‐α‐syn as part of a clinical evaluation for suspected MCI‐LB/DLB. Consensus MCI‐LB/DLB criteria blinded to skin biopsy result were applied through retrospective chart review; those not definitively meeting criteria were considered questionable synucleinopathy (QS). Results Median age at skin biopsy was 70 years (range, 43–87 years) with 81% men. 36 patients (68%) had positive skin biopsies. 32/43 (74%) patients meeting clinical consensus criteria for DLB/MCI‐LB had a positive skin biopsy, with higher frequency in MCI‐LB (87%) compared with DLB (60%). 4/10 (40%) QS had positive biopsies. One patient with a positive skin biopsy had no evidence of central nervous system (CNS) α‐syn on autopsy. Conclusions Positive skin biopsy for p‐α‐syn occurs across the spectrum of cognitive presentations of Lewy body disease including prodromal DLB, albeit at a lower frequency in this retrospective review of atypical cases compared with typical clinical presentations. A positive skin biopsy may not reflect CNS synucleinopathy as the etiology for a patient's symptoms in some cases. Longitudinal studies of skin biopsies for p‐α‐syn in suspected MCI‐LB/DLB with autopsy confirmation are needed. © 2025 International Parkinson and Movement Disorder Society.
Shared TCRs in peripheral blood offer robust celiac disease classification independent of gluten Intake
Elyanow, Rebecca , Marietta, Eric, Bharanikumar, Ramit, Zhou, Wenyu , Chen-Harris, Haiyin, Bhagat, Govind , Green, Peter H., Howie, Bryan, Robins, Harlan , Murray, Joseph A., Bhagat, Govind , Choung, Rok Seon , Chen‐Harris, Haiyin , Green, Peter H., Howie, Bryan, Neuhausen, Susan L. , Murray, Joseph A.

Mayo Clinic

No container title available | December 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.26.696039 Get It

Abstract Background and Aims Celiac disease (CeD) is a chronic digestive autoimmune disorder affecting approximately 1% of the worldwide population. It is driven by T cells activated by specific HLA-DQ2 or HLA-DQ8 molecules leading to the destruction of intestinal villi. We aimed to characterize shared CeD-specific T cells in patients on and off a gluten-free diet (GFD) from a large cohort of cases and controls. Methods We performed bulk TCRβ immune sequencing of the peripheral blood of 1,604 biopsy-confirmed CeD patients (1,339 on GFD, 265 on normal diet) and 1,100 controls. We identified over 300 TCRβs enriched in CeD cases versus controls in an HLA-aware manner, controlling for CeD risk alleles. Results CeD-associated TCRβs were found to be more predictive of disease than previously characterized gliadin and glutenin-binding TCRs in a validation cohort. Furthermore, the clonal breadth of these TCRβs was associated with increased intestinal damage. Immune sequencing of the peripheral blood also uncovered repertoire-level differences between CeD patients and controls. CeD patients displayed significantly higher productive clonality compared to age-matched controls as well as expansion of TCRβs specific to cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Conclusions These findings underscore the value of unbiased immune repertoire sequencing to identify novel biomarkers for autoimmune disease and to discover new disease mechanisms which can improve both diagnosis and treatment of disease.
A resource of data and samples in cognitively unimpaired persons at six levels of Alzheimer's disease risk based on their APOE genotype
Ghisays, Kathryn L., Brostrom, Deborah, Bauer, Robert, Devadas, Vivek, Salata, Hayley, Brown, Christopher , Walsh, Trisha, Liang, Winnie, Ashton, Nicholas, Geda, Yonas E., Huentelman, Matthew J. , Pruzin, Jeremy J. , Su, Yi, Caselli, Richard J., Woodruff, Bryan K. , Reiman, Eric M., Ghisays, Valentina , Geda, Yonas E. , Su, Yi, Caselli, Richard J. , Langbaum, Jessica B. S. , Reiman, Eric M.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_102172 Get It

Abstract Background Apolipoprotein E (APOE), the major genetic risk factor for Alzheimer's disease (AD), has three common alleles (2, 3 and 4), giving rise to genotypes that are associated with six levels of AD risk: (2/2<2/3<3/3<2/4<3/4<4/4). In our new Arizona APOE Cohort Study, we have begun to establish a longitudinal cohort of more than 300 cognitively unimpaired persons (50‐90 year‐old) stratified by APOE genotype and age decile, matched by age and sex, and have an extensive battery of cognitive, clinical, amyloid (NAV4694) and tau (MK6240) PET, MRI, cerebrospinal fluid (CSF), plasma, and DNA. The study is intended to clarify the impact of APOE4 and APOE2 allelic dose on the predisposition to and protection from AD and inform the design of secondary and primary prevention therapies. Here, we describe the study and the resource of data and samples that are now available to researchers. Methods Participants were recruited from across the United States using GeneMatch and other sources. Comprehensive clinical assessments, brain images, and lumbar punctures are performed every 2 years, 50mL blood samples are acquired annually, and whole genome sequencing is in progress. Results As of January 2025, baseline assessments were completed in 303 participants, 68±9 years of age, including 205 females and 98 males. Sixteen percent are from underrepresented groups. Baseline CSF samples were obtained in 89% of the participants. The complete cohort consists of 17, 63, 41, 65, 66, and 51 persons with the APOE 2/2, 2/3, 3/3, 2/4, 3/4, and 4/4 genotype, respectively. In the first 287 participants with available amyloid PET scans 6% of 2/2, 5% of 2/3, 14% of 3/3, 26% of 2/4, 29% of 3/4, and 52% of 4/4 participants had a positive amyloid PET (≥20 centiloids). Conclusions Building up on our decades of experience in APOE research, we launched the new Arizona APOE Cohort which promises to provide a valuable resource of data and samples to advance the study of APOE, its variants and interactions with other risk and protective factors, and the development, treatment, and prevention of AD. Baseline data are now available to interested and eligible research collaborators.
Navigating the Risks Beyond the Label: Unpacking Global Nutritional Supplement Safety
Wardenaar, Floris C. , Burns, Stephen F. , Campos, Marcus Vinícius Simões de , Chan, Yat C. , Claassen-Smithers, Amanda , Dunshea-Mooij, Christel A.E. , Haddou, Salah Eddine, Hoogervorst, Daan , García, P. , Garthe, Ina, Nugent, Anne P. , Aly, Maged Ossama , Schott, Kinta D. , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Campos, Marcus , Chan, Yat , Dunshea-Mooij, Christel , Jagim, Andrew R , Garcia, Pedro Reinaldo , Nugent, Anne P , Aly, Maged Ossama , Saunders, Bryan , Schott, Kinta D , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Stratton, Matthew T , Aussieker, Thorben , Jagim, Andrew R. , Stratton, Matthew T.

Mayo Clinic

International Journal of Sport Nutrition and Exercise Metabolism | December 17, 2025 | Volume: 36 | Issue: 2 | Pages: 134-166

10.1123/ijsnem.2025-0177 | PMID 41468235 Get It

Nutritional supplement use is common among athletes aiming to enhance performance, recovery, and health. However, variable regulatory frameworks and limited safety oversight create risks for inadvertent doping violations. This article provides a global overview of supplement use, relevant authorities, legislation, and safety measures, with a focus on third-party testing (TPT) as a risk-mitigation strategy. Data from six global regions—Africa, Asia, Australia/New Zealand, Europe, Latin America, and North America—were synthesized from peer-reviewed studies, governmental sources, and regional expert contributions. Reported supplement use ranged from 7% to 100% among athletes (variability within regions), with protein powders, vitamins/minerals, creatine, caffeine, and sports drinks being most prevalent. High-risk products (potential anti-doping rule violations), including certain herbal blends, preworkouts, and weight-management supplements, were reported across all regions. While some countries have robust regulatory systems, most lack harmonized or enforceable safety frameworks. TPT programs, which independently verify products for prohibited substances, remain concentrated in the global northwest (Europe, North America, and Australia/New Zealand); awareness and use of TPT certification vary widely, and even in regions with established systems, athlete adherence is inconsistent. Barriers to low-risk supplement use are limited TPT availability, cost, differences in labeling (including language), and cultural factors. Firsthand experiences and perceptions highlight widespread misconceptions about supplement safety and certification. The authors recommend expanded athlete and team-around-the-athlete education, improved global access to TPT low-risk supplements, and policy initiatives to harmonize safety standards. This work emphasizes the need for coordinated international efforts to protect athlete health and integrity while allowing access to evidence-based supplementation.